Sponsor: Gilead Sciences, Inc.
Sponsor Study ID: GS-US-682-6769 AND/OR GOG-3104/ENGOT-en26
Study Title: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
CTO #: 104078
NCT Number:
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Female Genital
Study Objectives: To compare the effect of sacituzumab govitecan (SG) relative to treatment of physician?s choice (TPC) on progression-free survival (PFS) as assessed by blinded independent central review (BICR). To compare the effect of SG relative to TPC on overall survival (OS).